CER-001

CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status. It is in early-stage clinical trials for the potential treatment of hypoalphalipoproteinaemia, acute coronary syndrome (ACS), acute kidney injury (AKI), atherosclerosis and lecithin cholesterol acyltransferase (LCAT) deficiency.

CER-001 is also under investigation as possible agent for treating hyperinflammatory states based on lipid profile alterations due to COVID-19.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1314200846 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

6 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.